Literature DB >> 22032720

Castleman disease in a pediatric liver transplant recipient: a case report and literature review.

Hugo J R Bonatti1, Jason Axt, Ellen Bailey Hunter, Sarah Louise Lott, Haydar Frangoul, Lynette Gillis, Hernan Correa, Beau Kelly.   

Abstract

Castleman disease is a rare hematologic disorder, closely linked to the HHV-8, and most commonly observed in immunocompromised individuals. Thirteen months following a liver transplant for CPS-1 defect, a 15-month-old boy presented with fevers, anemia, and growth retardation. Abdominal CT scan showed splenomegaly and generalized lymphadenopathy. Histology of chest wall lymph nodes revealed a mixed CD3+ T-cell and CD20+ B-cell population with atretic germinal centers consistent with multicentric Castleman disease. Qualitative DNA PCR detected HHV-8 in the resected lymph node and in the blood, supporting the diagnosis. Immunosuppression was tapered, and he was transitioned from tacrolimus to sirolimus. His graft function remained stable, and repeat imaging showed regression of the lymphadenopathy. The child is living one yr after Castleman disease diagnosis with a well-functioning graft. Castleman disease is a potential complication of solid organ transplant and HHV-8 infection. Reduction in immunosuppression and switch to sirolimus may be an effective strategy to treat this condition.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22032720     DOI: 10.1111/j.1399-3046.2011.01570.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  2 in total

1.  Castleman's Disease and Posttransplant Lymphoproliferative Disorder after Liver Transplant: 3-Year Follow-Up.

Authors:  Lokesh K Jha; Laura L Ulmer; Marco A Olivera-Martinez; Timothy M McCashland; Kai Fu; Fedja A Rochling
Journal:  Case Reports Hepatol       Date:  2018-01-28

2.  Multicentric Castleman's disease in a renal allograft recipient: a case report and literature review.

Authors:  Jinwen Lin; Shiping Yu; Rending Wang; Jianghua Chen
Journal:  J Int Med Res       Date:  2020-02       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.